Clinical Trial Update: Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating the combination of gemcitabine, bendamustine, and nivolumab in relapsed or refractory classical Hodgkin lymphoma has completed, with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Classical Hodgkin Lymphoma

Drugs mentioned

• Gemzar (gemcitabine)
• OPDIVO (nivolumab)
• Treanda (Bendamustine)

Snippet

Sponsor: Emory University | Conditions: Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-08-06